Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213038747> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3213038747 abstract "<h3>Introduction</h3> Immune Checkpoint Inhibitors (CPI) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refractory cases. However, robust outcome data for these patients are scarce. <h3>Methods</h3> We conducted a multi-centre (six cancer centres), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020. The primary outcome was corticosteroid-free clinical remission (CFCR) with CTCAE grade 0 for diarrhoea at 12 weeks after IFX initiation. We also assessed cancer outcomes at one year using RECIST criteria. <h3>Results</h3> 127 patients (73 male; median age 59 years) were treated with IFX for corticosteroid-refractory CPI-induced enterocolitis. Ninety-six (75.6%) patients had diarrhoea CTCAE grade >2 and 115 (90.6%) required hospitalisation for colitis. CFCR was 41.2% at 12 weeks and 50.9% at 26 weeks. In multivariable logistical regression, IFX-resistant enterocolitis was associated with rectal bleeding (OR 0.19; 95% CI 0.04-0.80; p=0.03) and absence of colonic crypt abscesses (OR 2.16; 95% CI 1.13-8.05; p=0.03). Cancer non-progression was significantly more common in patients with IFX-resistant enterocolitis (64.4%) as compared to patients with IFX-responsive enterocolitis (37.5%; p=0.013). <h3>Conclusion</h3> This is the largest study to date reporting outcomes of IFX therapy in patients with corticosteroid-refractory CPI-induced enterocolitis. Utilizing pre-defined robust endpoints, we have demonstrated that fewer than half of patients achieved CFCR. Our data also indicate that cancer outcomes may be better in patients developing prolonged and severe inflammatory side effects of CPI-therapy." @default.
- W3213038747 created "2021-11-22" @default.
- W3213038747 creator A5001255955 @default.
- W3213038747 creator A5009737345 @default.
- W3213038747 creator A5013066121 @default.
- W3213038747 creator A5032060766 @default.
- W3213038747 creator A5041312321 @default.
- W3213038747 creator A5047051074 @default.
- W3213038747 creator A5053475330 @default.
- W3213038747 creator A5059369253 @default.
- W3213038747 creator A5066982461 @default.
- W3213038747 creator A5085367592 @default.
- W3213038747 date "2021-11-01" @default.
- W3213038747 modified "2023-09-26" @default.
- W3213038747 title "ATU-2 A multi-centre study of Infliximab treatment for corticosteroid-refractory Checkpoint Inhibitor Induced enterocolitis" @default.
- W3213038747 doi "https://doi.org/10.1136/gutjnl-2021-bsg.40" @default.
- W3213038747 hasPublicationYear "2021" @default.
- W3213038747 type Work @default.
- W3213038747 sameAs 3213038747 @default.
- W3213038747 citedByCount "0" @default.
- W3213038747 crossrefType "proceedings-article" @default.
- W3213038747 hasAuthorship W3213038747A5001255955 @default.
- W3213038747 hasAuthorship W3213038747A5009737345 @default.
- W3213038747 hasAuthorship W3213038747A5013066121 @default.
- W3213038747 hasAuthorship W3213038747A5032060766 @default.
- W3213038747 hasAuthorship W3213038747A5041312321 @default.
- W3213038747 hasAuthorship W3213038747A5047051074 @default.
- W3213038747 hasAuthorship W3213038747A5053475330 @default.
- W3213038747 hasAuthorship W3213038747A5059369253 @default.
- W3213038747 hasAuthorship W3213038747A5066982461 @default.
- W3213038747 hasAuthorship W3213038747A5085367592 @default.
- W3213038747 hasBestOaLocation W32130387471 @default.
- W3213038747 hasConcept C121332964 @default.
- W3213038747 hasConcept C126322002 @default.
- W3213038747 hasConcept C141071460 @default.
- W3213038747 hasConcept C142424586 @default.
- W3213038747 hasConcept C167135981 @default.
- W3213038747 hasConcept C17991360 @default.
- W3213038747 hasConcept C2776258884 @default.
- W3213038747 hasConcept C2776804153 @default.
- W3213038747 hasConcept C2777138892 @default.
- W3213038747 hasConcept C71924100 @default.
- W3213038747 hasConcept C87355193 @default.
- W3213038747 hasConcept C90924648 @default.
- W3213038747 hasConceptScore W3213038747C121332964 @default.
- W3213038747 hasConceptScore W3213038747C126322002 @default.
- W3213038747 hasConceptScore W3213038747C141071460 @default.
- W3213038747 hasConceptScore W3213038747C142424586 @default.
- W3213038747 hasConceptScore W3213038747C167135981 @default.
- W3213038747 hasConceptScore W3213038747C17991360 @default.
- W3213038747 hasConceptScore W3213038747C2776258884 @default.
- W3213038747 hasConceptScore W3213038747C2776804153 @default.
- W3213038747 hasConceptScore W3213038747C2777138892 @default.
- W3213038747 hasConceptScore W3213038747C71924100 @default.
- W3213038747 hasConceptScore W3213038747C87355193 @default.
- W3213038747 hasConceptScore W3213038747C90924648 @default.
- W3213038747 hasLocation W32130387471 @default.
- W3213038747 hasOpenAccess W3213038747 @default.
- W3213038747 hasPrimaryLocation W32130387471 @default.
- W3213038747 hasRelatedWork W1793302197 @default.
- W3213038747 hasRelatedWork W1997083736 @default.
- W3213038747 hasRelatedWork W2087055336 @default.
- W3213038747 hasRelatedWork W2172472108 @default.
- W3213038747 hasRelatedWork W2315343720 @default.
- W3213038747 hasRelatedWork W2528057197 @default.
- W3213038747 hasRelatedWork W2795832935 @default.
- W3213038747 hasRelatedWork W3113146271 @default.
- W3213038747 hasRelatedWork W4232677788 @default.
- W3213038747 hasRelatedWork W2187546221 @default.
- W3213038747 isParatext "false" @default.
- W3213038747 isRetracted "false" @default.
- W3213038747 magId "3213038747" @default.
- W3213038747 workType "article" @default.